CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences bleeding risk. Major bleeding, subsequent myocardial infarct ...


Interim results from the ongoing phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen ( AGT ) for the treatment of hypertension, were ann ...


Troponin elevation is common in hospitalized COVID-19 patients, but underlying aetiologies are ill-defined. Researchers have used multi-parametric cardiovascular magnetic resonance ( CMR ) to assess ...


Mavacamten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy ( HCM ), according to results from the EXPLORER-HCM trial. Currently available medical treat ...


The coronavirus disease 2019 ( COVID-19 ) pandemic has resulted in severe psychological, social, and economic stress in people’s lives. It is not known whether the stress of the pandemic is associated ...



New data from a sub-analysis of the landmark phase III DAPA-HF ( Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure ) trial have shown that Dapagliflozin ( Farxiga ) has reduced the inc ...


COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying heart conditions. Experts have known that viral i ...


Elevated apolipoprotein C-III ( apoC-III ) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an N-acetyl galactosamine-conjugated antisense oligonucle ...


The CANVAS trial has shown that Canagliflozin ( Invokana ) was superior to placebo at preventing cardiovascular events. The goal of the trial was to evaluate the sodium-glucose cotransporter 2 inhi ...


Although procedure-related deaths during index admission following catheter ablation of atrial fibrillation ( AF ) have been reported to be low, adverse outcomes can occur after discharge. There are ...


The aim of study was to compare effectiveness and safety of non-vitamin K antagonist oral anticoagulants ( NOACs ) versus vitamin-K antagonists ( VKA ) in atrial fibrillation ( AF) patients with chron ...


Ivabradine ( Corlanor ) has been approved in heart failure with reduced ejection fraction ( HFrEF ) and elevated heart rate despite guideline-directed medical therapy ( GDMT ) to reduce cardiovascular ...


The GLOBAL LEADERS ( GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation ) trial randomly assigned 15,991 patients undergoing percutaneous coronary i ...


The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on for a therapy that can improve health outcomes in this group of patients for whom no app ...